Sponsor Pipeline

Chipscreen Biosciences, Ltd. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
14
Active Trials
7
Recruiting
4
Phase 3
10
Disease Areas
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-02 NCT05271292
Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
overall status: Recruiting → Unknown
Active Trials by Phase
Phase 3
4
Phase 2
1
Phase 1/2
1
Phase 1
5
Not specified
3
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT04921527 Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or… Ovarian Cancer Recruiting
NCT06947967 Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With… Lymphoma, T-Cell, Peripheral Recruiting
NCT06497985 A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR… Colorectal Cancer Recruiting
NCT07445295 Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With… Metastatic Pancreatic Ductal Adenocarcinoma Not Yet Recruiting
Phase 2
NCT06492915 Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal… Pancreatic Ductal Adenocarcinoma Active, Not Recruiting
Phase 1/2
NCT07129382 A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to… Plaque Psoriasis Recruiting
Phase 1
NCT05979155 A Study of NWY001 in Subjects With Advanced Solid Tumors Advanced Solid Tumor Recruiting
NCT06902350 Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors Neoplasms Recruiting
NCT06245122 A Study of CS23546 in Subjects With Advanced Tumors Advanced Tumors Recruiting
NCT07511010 Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets T2DM (Type 2 Diabetes Mellitus) Not Yet Recruiting
NCT07583771 A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma Pancreatic Adenocarcinoma Not Yet Recruiting
Not specified
NCT07412015 Pilot Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets T2DM (Type 2 Diabetes Mellitus) Not Yet Recruiting
NCT07519265 Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets T2DM (Type 2 Diabetes Mellitus) Not Yet Recruiting
NCT07580638 Chiglitazar Added to SGLT-2 Inhibitors for Type 2 Diabetes T2DM (Type 2 Diabetes Mellitus) Not Yet Recruiting
Disease Areas
Get alerts when Chipscreen Biosciences, Ltd.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free